| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 252 | 2019 |
| Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study A Gafita, J Calais, TR Grogan, B Hadaschik, H Wang, M Weber, S Sandhu, ... The Lancet Oncology 22 (8), 1115-1125, 2021 | 178 | 2021 |
| EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds M Weber, M Lam, C Chiesa, M Konijnenberg, M Cremonesi, P Flamen, ... European journal of nuclear medicine and molecular imaging 49 (5), 1682-1699, 2022 | 135 | 2022 |
| Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients J Ferdinandus, PF Costa, L Kessler, M Weber, N Hirmas, K Kostbade, ... Journal of Nuclear Medicine 63 (5), 727-734, 2022 | 129 | 2022 |
| Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study A Gafita, I Rauscher, M Weber, B Hadaschik, H Wang, WR Armstrong, ... Journal of Nuclear Medicine 63 (11), 1651-1658, 2022 | 110 | 2022 |
| PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis R Seifert, K Kessel, K Schlack, M Weber, K Herrmann, M Spanke, ... European Journal of Nuclear Medicine and Molecular Imaging 48, 1200-1210, 2021 | 106 | 2021 |
| Artificial intelligence and machine learning in nuclear medicine: future perspectives R Seifert, M Weber, E Kocakavuk, C Rischpler, D Kersting Seminars in nuclear medicine 51 (2), 170-177, 2021 | 100 | 2021 |
| Pitfalls and common findings in 68Ga-FAPI PET: a pictorial analysis L Kessler, J Ferdinandus, N Hirmas, F Zarrad, M Nader, D Kersting, ... Journal of Nuclear Medicine 63 (6), 890-896, 2022 | 86 | 2022 |
| Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities WP Fendler, KM Pabst, L Kessler, P Fragoso Costa, J Ferdinandus, ... Clinical Cancer Research 28 (19), 4346-4353, 2022 | 82 | 2022 |
| Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria A Gafita, I Rauscher, WP Fendler, V Murthy, W Hui, WR Armstrong, ... European Journal of Nuclear Medicine and Molecular Imaging 49 (12), 4271-4281, 2022 | 65 | 2022 |
| Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality? A Gafita, H Wang, A Robertson, WR Armstrong, R Zaum, M Weber, ... Journal of Nuclear Medicine 63 (2), 226-232, 2022 | 62 | 2022 |
| 68Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma N Hirmas, C Leyh, M Sraieb, F Barbato, BM Schaarschmidt, L Umutlu, ... Journal of Nuclear Medicine 62 (9), 1235-1241, 2021 | 57 | 2021 |
| Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study A Gafita, WP Fendler, W Hui, S Sandhu, M Weber, R Esfandiari, J Calais, ... European Urology 78 (2), 148-154, 2020 | 56 | 2020 |
| Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of … M Weber, L Kessler, B Schaarschmidt, WP Fendler, H Lahner, G Antoch, ... BMC cancer 20, 1-12, 2020 | 55 | 2020 |
| Hybrid 11C-MET PET/MRI combined with “machine learning” in glioma diagnosis according to the revised glioma WHO classification 2016 S Kebir, M Weber, L Lazaridis, C Deuschl, T Schmidt, C Mönninghoff, ... Clinical nuclear medicine 44 (3), 214-220, 2019 | 55 | 2019 |
| Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study M Weber, D Kersting, B Riemann, T Brandenburg, D Führer-Sakel, ... Clinical Cancer Research 28 (19), 4194-4202, 2022 | 48 | 2022 |
| 68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study A Farolfi, A Gafita, J Calais, M Eiber, A Afshar-Oromieh, F Spohn, ... The Journal of urology 202 (6), 1174-1181, 2019 | 48 | 2019 |
| Equivalent tumor detection for early and late FAPI-46 PET acquisition J Ferdinandus, L Kessler, N Hirmas, M Trajkovic-Arsic, R Hamacher, ... European journal of nuclear medicine and molecular imaging, 1-7, 2021 | 47 | 2021 |
| Vianney de Jong BN Smith, S Newhouse, A Shatunov, C Vance, S Topp, L Johnson, ... JM, Baas, F., Andersen, PM, Landers, J., Brown Jr., RH, Weale, ME, Al …, 2013 | 47 | 2013 |
| Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy A Pechmann, M Behrens, K Dörnbrack, A Tassoni, S Stein, S Vogt, ... Brain 146 (2), 668-677, 2023 | 41 | 2023 |
